Neurogene Reports $65.4 Million Net Loss and Increased R&D Expenses for First Half of 2026

Neurogene Inc. reported a net loss of $65.4 million for the six months ended June 30, 2026, compared to a net loss of $44.7 million for the same period in 2025, reflecting an increase of 46.3%. The company's total operating expenses rose to $70 million, up from $52 million year-over-year, driven primarily by increased research and development costs associated with its lead program, NGN-401, which is in clinical trials for the treatment of Rett syndrome. Research and development expenses for the first half of 2026 were $50.6 million, compared to $37.1 million in the prior year, marking a 36.3% increase. General and administrative expenses also increased to $19.4 million from $14.9 million, largely due to higher personnel costs and stock-based compensation.

In terms of financial position, Neurogene's total assets decreased to $244.4 million as of June 30, 2026, down from $288.6 million at the end of 2025. The decline was primarily attributed to a reduction in short-term investments, which fell from $165.2 million to $112.9 million. The company reported cash and cash equivalents of $112.5 million, an increase from $103.8 million at the end of 2025. The accumulated deficit also widened to $418.1 million, up from $352.6 million at the end of the previous fiscal year.

Strategically, Neurogene has made significant advancements in its clinical programs, particularly with NGN-401. The company has completed dosing in its registrational trial, Embolden, which is designed to support a potential Biologics License Application (BLA) submission. The trial has shown promising results, with all participants improving in key developmental milestones. Additionally, Neurogene has received Breakthrough Therapy designation from the FDA for NGN-401, which is expected to expedite its development process.

Operationally, Neurogene has expanded its workforce to support its growing clinical and administrative needs, with an increase in employee headcount contributing to higher operational costs. The company has also enhanced its manufacturing capabilities at its facility in Houston, Texas, which is now fully operational and compliant with current good manufacturing practices (cGMP). This facility is expected to play a crucial role in the production of clinical-grade materials for ongoing and future trials.

Looking ahead, Neurogene anticipates continued financial losses as it advances its clinical programs and invests in research and development. The company has raised approximately $134.8 million from a public offering completed in July 2026, which it expects will provide sufficient capital to fund operations into early 2029. However, management acknowledges the need for additional capital to support ongoing and future initiatives, including potential commercialization efforts for its product candidates.